{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:13:41Z","timestamp":1788671621381,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaclp.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:21:31Z","timestamp":1741627291000},"page":"230-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic Review of Neuropsychiatric Toxicity in Second Generation Antifungals With an Illustrative Case Report"],"prefix":"10.1016","volume":"66","author":[{"given":"Justine","family":"Leveque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Merveilleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0042-3118","authenticated-orcid":false,"given":"Maxime","family":"Tiberghien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jaclp.2025.03.001_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/imj.15586","article-title":"Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021","volume":"51 Suppl 7","author":"Khanina","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaclp.2025.03.001_bib39","article-title":"Antifungal prophylaxis and pre-emptive therapy: When and how?","volume":"92","author":"Sprute","year":"2023","journal-title":"Mol Aspects Med. ao\u00fbt"},{"key":"10.1016\/j.jaclp.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent. Saravolatz LD, \u00e9diteur","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaclp.2025.03.001_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaclp.2025.03.001_bib3","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/jac\/dky270","article-title":"Trends in antifungal use in US hospitals, 2006\u201312","volume":"73","author":"Vallabhaneni","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jaclp.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"e1-60","DOI":"10.1093\/cid\/ciw444","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaclp.2025.03.001_bib5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1167\/iovs.14-15270","article-title":"Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels","volume":"56","author":"Xiong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaclp.2025.03.001_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s15010-004-3121-1","article-title":"Voriconazole-induced musical hallucinations","volume":"32","author":"Agrawal","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.jaclp.2025.03.001_bib7","first-page":"632","article-title":"Hallucinosis as side effect of voriconazole","volume":"205","author":"Flox","year":"2005","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.jaclp.2025.03.001_bib8","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jaclp.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaclp.2025.03.001_bib10","doi-asserted-by":"crossref","first-page":"e7-e10","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jaclp.2025.03.001_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-008-0114-3","article-title":"Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population","volume":"88","author":"Imataki","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib12","first-page":"804","article-title":"Adverse drug events complicate antifungal therapy for pulmonary aspergilloma","volume":"23","author":"Pakyz","year":"2008","journal-title":"Consult Pharm J Am Soc Consult Pharm"},{"key":"10.1016\/j.jaclp.2025.03.001_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.medcli.2008.09.022","article-title":"Alucinaciones visuales complejas inducidas por voriconazol","volume":"133","author":"Fern\u00e1ndez-Ruiz","year":"2009","journal-title":"Med Cl\u00ednica"},{"key":"10.1016\/j.jaclp.2025.03.001_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1445-5994.2011.02454.x","article-title":"Voriconazole toxicity related to polymorphisms in CYP2C19","volume":"41","author":"Suan","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaclp.2025.03.001_bib15","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaclp.2025.03.001_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0253-7613.157136","article-title":"Voriconazole-induced psychosis in a case of acute myeloid leukemia with febrile neutropenia","volume":"47","author":"Singh","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/15569527.2015.1020544","article-title":"Voriconazole-associated visual disturbances and hallucinations","volume":"35","author":"Bayhan","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib18","first-page":"660","article-title":"An investigation of visual hallucinations associated with voriconazole adminstration to patients with hematological malignancies","volume":"71","author":"Sakurada","year":"2016","journal-title":"Pharmazie"},{"key":"10.1016\/j.jaclp.2025.03.001_bib19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.02739-15","article-title":"Visual hallucinations associated with high posaconazole concentrations in serum","volume":"60","author":"Parkes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaclp.2025.03.001_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw215","article-title":"Elevated voriconazole level associated with hallucinations and suicidal ideation: a case report","volume":"4","author":"Jansen","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaclp.2025.03.001_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.riam.2019.04.003","article-title":"[Otomastoiditis due to Scedosporium apiospermum. Hallucinations as an adverse reaction to voriconazol]","volume":"36","author":"Fuster-Escriv\u00e1","year":"2019","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/myc.13080","article-title":"Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events","volume":"63","author":"Jiang","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.jaclp.2025.03.001_bib23","article-title":"Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-254790","article-title":"Voriconazole-induced psychosis in rhino-orbital invasive aspergillosis","volume":"16","author":"Rekha","year":"2023","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaclp.2025.03.001_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63504-y","article-title":"Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database","volume":"14","author":"Kato","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaclp.2025.03.001_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaclp.2025.03.001_bib27","doi-asserted-by":"crossref","first-page":"31783","DOI":"10.1074\/jbc.M110.143313","article-title":"Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain","volume":"285","author":"Mast","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaclp.2025.03.001_bib28","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1073\/pnas.0600316103","article-title":"Brain cholesterol turnover required for geranylgeraniol production and learning in mice","volume":"103","author":"Kotti","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaclp.2025.03.001_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jaclp.2025.03.001_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jaclp.2025.03.001_bib31","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/AAC.02809-13","article-title":"Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis","volume":"58","author":"Liu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaclp.2025.03.001_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101114","article-title":"Retinal TRP channels: cell-type-specific regulators of retinal homeostasis and multimodal integration","volume":"92","author":"Kri\u017eaj","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jaclp.2025.03.001_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2843","article-title":"Transient receptor potential ion channels and cerebral stroke","volume":"13","author":"Xu","year":"2023","journal-title":"Brain Behav"},{"key":"10.1016\/j.jaclp.2025.03.001_bib34","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1177\/0192623309348521","article-title":"Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects","volume":"37","author":"Cartwright","year":"2009","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jaclp.2025.03.001_bib35","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.febslet.2006.08.061","article-title":"Drug-induced phospholipidosis","volume":"580","author":"Anderson","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jaclp.2025.03.001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100089","article-title":"Inhibition of lysosomal phospholipase A2 predicts drug-induced phospholipidosis","volume":"62","author":"Hinkovska-Galcheva","year":"2021","journal-title":"J Lipid Res"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296025000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296025000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:05:29Z","timestamp":1749906329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296025000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2667296025000291"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2025.03.001","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Neuropsychiatric Toxicity in Second Generation Antifungals With an Illustrative Case Report","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Academy of Consultation-Liaison Psychiatry.","name":"copyright","label":"Copyright"}]}}